Blockade of 5-HT2a Receptors Reduces Haloperidol-Induced Attenuation of Reward

Previous studies have shown that effective antipsychotic medications attenuate reward, an effect that is generally attributed to their effectiveness at blocking the dopamine D2-like receptors. As blockade of the serotonin type 2a (5-HT2a) receptors is a common property of the newer antipsychotics, the present study compared the effect of haloperidol, clozapine, and M100907 (a selective 5-HT2a antagonist) and the combined effect of haloperidol and M100907 treatment on brain stimulation reward (BSR). Experiments were performed on male Sprague–Dawley rats trained to produce an operant response to obtain electrical stimulation in the lateral hypothalamus. Measures of reward threshold were determined in different groups of rats using the curve-shift method using fixed current intensity and variable frequency before and at different times after injection of haloperidol (0.01, 0.05, 0.1, and 0.25 mg/kg), clozapine (1, 7.5, 15, and 30 mg/kg), M100907 (0.033, 0.1, and 0.3 mg/kg), or their vehicle. The effect of M100907 (0.3 mg/kg) on the attenuation of BSR by a sub- and suprathreshold dose of haloperidol was studied in another group of rats. Clozapine produced a dose-orderly increase in reward threshold with a mean maximal increase of 50%; at high doses, clozapine induced cessation of responding in several animals at different time periods. Haloperidol induced a dose-dependent increase in reward threshold, with the mean maximal increase (75%) being observed at the highest dose; it also produced a dose-dependent reduction of maximum rates of responding. M100907 failed to alter reward at any of the doses tested and had no effect on the subthreshold dose (0.01 mg/kg) of haloperidol. But when combined with a suprathreshold dose of haloperidol, M100907 reduced the reward-attenuating effect of haloperidol. These results show that 5-HT2a receptors are unlikely to constitute a component of the reward-relevant pathway activated by lateral hypothalamic stimulation. However, blockade of 5-HT2a receptors may account for the relatively lower level of reward attenuation produced by clozapine, and predict that antipsychotic medications that have a high affinity for the 5-HT2a receptor may be less likely to induce dysphoria.

[1]  Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation GALLISTEL, C. R. AND A. J. DAVIS. PHARMACOL BIOCHEM BEHAV 19(5) 867–872, 1983 , 1983, Pharmacology Biochemistry and Behavior.

[2]  K. Franklin,et al.  The influence of amphetamine on preference for lateral hypothalamic versus prefrontal cortex or ventral tegmental area self-stimulation , 1983, Pharmacology Biochemistry and Behavior.

[3]  C. Gallistel,et al.  Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation , 1983, Pharmacology Biochemistry and Behavior.

[4]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[5]  P. Shizgal,et al.  The substrates for self-stimulation of the lateral hypothalamus and medial prefrontal cortex: A comparison of strength-duration characteristics , 1985, Physiology & Behavior.

[6]  P. Rompré,et al.  The curve-shift paradigm in self-stimulation , 1986, Physiology & Behavior.

[7]  F. Mora,et al.  Neurotransmitters, pathways and circuits as the neural substrates of self-stimulation of the prefrontal cortex: Facts and speculations , 1986, Behavioural Brain Research.

[8]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[9]  R. Wise,et al.  Effects of nucleus accumbens amphetamine on lateral hypothalamic brain stimulation reward , 1988, Brain Research.

[10]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[11]  R. Wise,et al.  Brain dopamine and reward. , 1989, Annual review of psychology.

[12]  Norio Ozaki,et al.  increased dopamine and serotonin metabolism in rat nucleus accumbens produced by intracranial self-stimulation of medial forebrain bundle as measured by in vivo microdialysis , 1989, Brain Research.

[13]  D. Corbett,et al.  Regional neuroleptic microinjections indicate a role for nucleus accumbens in lateral hypothalamic self-stimulation reward , 1989, Brain Research.

[14]  A. Robertson Multiple reward systems and the prefrontal cortex , 1989, Neuroscience & Biobehavioral Reviews.

[15]  D. Corbett Ketamine blocks the plasticity associated with prefrontal cortex self-stimulation , 1990, Pharmacology Biochemistry and Behavior.

[16]  C. Blaha,et al.  Application of in vivo electrochemistry to the measurement of changes in dopamine release during intracranial self-stimulation , 1990, Journal of Neuroscience Methods.

[17]  N. Ozaki,et al.  Differential effect of self-stimulation on dopamine release and metabolism in the rat medial frontal cortex, nucleus accumbens and striatum studied by in vivo microdialysis , 1992, Brain Research.

[18]  J. Kehne,et al.  Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. , 1993, The Journal of pharmacology and experimental therapeutics.

[19]  Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. , 1993 .

[20]  Differential effects of ondansetron, haloperidol and clozapine on electrical self‐stimulation of the ventral tegmental area , 1993, Behavioural pharmacology.

[21]  R. Beninger,et al.  Rostral-caudal differences in effects of nucleus accumbens amphetamine on VTA ICSS , 1994, Brain Research.

[22]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[24]  J. Kehne,et al.  Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist , 1995, Behavioural Brain Research.

[25]  P. Rompré Psychostimulant-like effect of central microinjection of neurotensin on brain stimulation reward , 1995, Peptides.

[26]  T. Svensson,et al.  Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat , 1996, European Neuropsychopharmacology.

[27]  P. Rompré,et al.  Effect of pimozide on self-stimulation thresholds under a continuous and fixed-interval schedule of reinforcement , 1996, Behavioural Brain Research.

[28]  S. Nakajima,et al.  The involvement of dopamine D2 receptors, but not D3 or D4 receptors, in the rewarding effect of brain stimulation in the rat , 1997, Brain Research.

[29]  T. Raju,et al.  Dopamine receptor sub-types involvement in nucleus accumbens and ventral tegmentum but not in medial prefrontal cortex: on self-stimulation of lateral hypothalamus and ventral mesencephalon , 1997, Behavioural Brain Research.

[30]  K. Young,et al.  Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907 , 1998, Biological Psychiatry.

[31]  P. Salmi,et al.  Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. , 1998, Pharmacology & toxicology.

[32]  Prefrontal cortex infusions of SCH 23390 cause immediate and delayed effects on ventral tegmental area stimulation reward , 1998, Brain Research.

[33]  H. Meltzer The Role of Serotonin in Antipsychotic Drug Action , 1999, Neuropsychopharmacology.

[34]  S. Leucht,et al.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials , 1999, Schizophrenia Research.

[35]  P. Hicks,et al.  The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? , 1999, Neuroscience & Biobehavioral Reviews.

[36]  P. Rompré,et al.  Behavioral Evidence of Depolarization Block of Dopamine Neurons after Chronic Treatment with Haloperidol and Clozapine , 2000, The Journal of Neuroscience.

[37]  P. Shizgal,et al.  Fos expression following self-stimulation of the medial prefrontal cortex , 2000, Behavioural Brain Research.

[38]  V. Pickel,et al.  Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area , 2000, Brain Research.

[39]  T. Tzschentke,et al.  The medial prefrontal cortex as a part of the brain reward system , 2000, Amino Acids.

[40]  D. Nakahara,et al.  Intracranial self-stimulation increases differentially in vivo hydroxylation of tyrosine but similarly in vivo hydroxylation of tryptophan in rat medial prefrontal cortex, nucleus accumbens and striatum , 2000, Brain Research.

[41]  Marc Laruelle,et al.  The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies , 2000, Brain Research Reviews.

[42]  J. Browning,et al.  Antagonism at 5-HT2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats , 2001, Pharmacology Biochemistry and Behavior.

[43]  K. Cunningham,et al.  Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[44]  H. Meltzer,et al.  Psychosis and drug dependence: results from a national survey of prisoners. , 2002, The British journal of psychiatry : the journal of mental science.

[45]  H. Meltzer,et al.  5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner , 2002, Brain Research.

[46]  H. Meltzer,et al.  5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. , 2002, Brain Research.

[47]  H. Meltzer,et al.  SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens , 2002, Neuropsychopharmacology.

[48]  H. Meltzer,et al.  5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. , 2003, Brain research.

[49]  S. Kapur,et al.  Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[50]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[51]  H. Meltzer,et al.  5-HT2A receptor stimulation by DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens , 2003, Brain Research.

[52]  A. Awad,et al.  Neuroleptic dysphoria: towards a new synthesis , 2003, Psychopharmacology.

[53]  C. Correll,et al.  Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. , 2003, The American journal of psychiatry.

[54]  T. Svensson,et al.  Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[55]  T. van Amelsvoort,et al.  Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications , 2004 .

[56]  Second-Generation Antipsychotics: Looking beyond Efficacy , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[57]  C. Kruse,et al.  5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat , 2004, Neuropharmacology.

[58]  D. Murphy,et al.  Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors , 2005, Psychopharmacology.

[59]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[60]  J. Kehne,et al.  Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function , 2005, Psychopharmacology.

[61]  The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro. , 2005, European journal of pharmacology.